Mazor Robotics Ltd – (NASDAQ:MZOR)’s share price hit a new 52-week high on Thursday . The company traded as high as $21.47 and last traded at $21.24, with a volume of 171,193 shares changing hands. The stock had previously closed at $19.52.

A number of brokerages have recently weighed in on MZOR. Needham & Company LLC reiterated a “hold” rating on shares of Mazor Robotics Ltd – in a report on Wednesday, July 13th. Zacks Investment Research upgraded Mazor Robotics Ltd – from a “sell” rating to a “hold” rating in a report on Thursday, May 19th. Barclays PLC upped their target price on Mazor Robotics Ltd – from $16.00 to $23.00 and gave the company an “overweight” rating in a report on Thursday, July 14th. Standpoint Research assumed coverage on Mazor Robotics Ltd – in a report on Friday, July 8th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, Sterne Agee CRT downgraded Mazor Robotics Ltd – from a “buy” rating to a “neutral” rating in a report on Tuesday, May 31st. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $25.00.

The stock’s market cap is $469.31 million. The company has a 50-day moving average price of $18.43 and a 200-day moving average price of $13.21.

Mazor Robotics Ltd – (NASDAQ:MZOR) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.06. The firm earned $6.40 million during the quarter, compared to analyst estimates of $6.63 million. During the same quarter in the previous year, the business earned ($0.11) earnings per share. Mazor Robotics Ltd -‘s revenue for the quarter was up 42.2% compared to the same quarter last year. Analysts expect that Mazor Robotics Ltd – will post ($0.44) EPS for the current fiscal year.

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.